516
Views
8
CrossRef citations to date
0
Altmetric
Research Article

CP-MLR/PLS directed QSAR study on the glutaminyl cyclase inhibitory activity of imidazoles: rationales to advance the understanding of activity profile

, , &
Pages 515-522 | Received 18 Mar 2011, Accepted 29 Dec 2011, Published online: 05 Feb 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Articles from other publishers (7)

Daoyuan Chen, Qingxiu Chen, Xiaofei Qin, Peipei Tong, Liping Peng, Tao Zhang & Chunli Xia. (2023) Development and evolution of human glutaminyl cyclase inhibitors (QCIs): an alternative promising approach for disease-modifying treatment of Alzheimer's disease. Frontiers in Aging Neuroscience 15.
Crossref
Kiran Bagri, Ashwani Kumar, Parvin Kumar, Archana Kapoor & Vikas Verma. 2023. Computational Modeling of Drugs Against Alzheimer’s Disease. Computational Modeling of Drugs Against Alzheimer’s Disease 383 403 .
Nusrat Sahiba, Pankaj Teli, Dinesh K. Agarwal & Shikha Agarwal. 2022. Imidazole-Based Drug Discovery. Imidazole-Based Drug Discovery 291 322 .
Chenshu Xu, Yi-nan Wang & Haiqiang Wu. (2021) Glutaminyl Cyclase, Diseases, and Development of Glutaminyl Cyclase Inhibitors. Journal of Medicinal Chemistry 64:10, pages 6549-6565.
Crossref
Judite RM Coimbra, Pedro JM Sobral, Armanda E Santos, Paula I Moreira & Jorge AR Salvador. (2019) An overview of glutaminyl cyclase inhibitors for Alzheimer’s disease. Future Medicinal Chemistry 11:24, pages 3179-3194.
Crossref
Rinnie, Vikas Gaba, Ketki Rani, Shilpa & Manish K. Gupta. (2019) QSAR study on 4-alkynyldihydrocinnamic acid analogs as free fatty acid receptor 1 agonists and antidiabetic agents: Rationales to improve activity. Arabian Journal of Chemistry 12:7, pages 1758-1764.
Crossref
Sourav Kalra, Ankit Kumar & Manish K. Gupta. (2012) Modeling of antitubercular activity of biphenyl analogs of 2-nitroimidazo[2,1-b][1,3]oxazine to rationalize their activity profile. Medicinal Chemistry Research 22:7, pages 3444-3451.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.